Integration of ncAA side chains that induce steric hindrance against proteases or facilitate site-specific macrocyclization, thereby extending serum half-life and improving bioavailability.
As a preclinical service provider in next-generation genetic code expansion (GCE), our company provides an integrated platform for incorporating non-canonical amino acids (ncAAs) into proteins with high fidelity. This technology unlocks novel approaches in therapeutic development, particularly for immunomodulatory peptides. By enabling the site-specific introduction of unique chemical functionalities, our proprietary GCEngine platform facilitates the creation of peptide therapeutics with enhanced stability, activity, and multifunctional capabilities. We support clients from discovery through preclinical development with tailored, high-throughput solutions for advanced pharmaceutical and synthetic biology applications.
Immunomodulatory peptide therapy utilizes designed amino acid sequences to precisely regulate immune responses, offering targeted intervention strategies for autoimmune diseases, oncology, and chronic inflammatory disorders. These peptides can function as agonists or antagonists for specific immune receptors (e.g., cytokine receptors, checkpoint molecules), modulate signal transduction pathways, or influence immune cell trafficking and differentiation. While promising, native peptides often face limitations such as rapid proteolytic degradation, poor pharmacokinetics, and insufficient target specificity. Advanced engineering strategies are therefore critical to realizing their full therapeutic potential.
Enhanced Metabolic Stability
Integration of ncAA side chains that induce steric hindrance against proteases or facilitate site-specific macrocyclization, thereby extending serum half-life and improving bioavailability.
Site-Specific Functionalization
Incorporation of ncAAs with functional "handles" for click-chemistry mediated conjugation of PEG, fatty acids, or cytotoxic payloads without interfering with the intrinsic biological activity of the peptide.
Optimized Binding Affinity
Introduction of ncAAs with novel side-chain chemistries allows for the creation of tailored interactions within the immune receptor binding interface. This can fine-tune binding affinity, alter signaling bias, or enhance target selectivity.
Reduced Immunogenicity Risk
Strategic replacement of specific residues with ncAAs can alter peptide conformation and surface properties, potentially masking epitopes that might elicit undesirable anti-drug antibody (ADA) responses.
Leveraging our proprietary high-throughput orthogonal aaRS/tRNA pairs development platform, we offer end-to-end services for engineering advanced immunomodulatory peptides. Our capabilities span the identification of optimal orthogonal pairs for specific ncAAs, in vitro validation of efficient and faithful ncAA incorporation into target peptide sequences, and subsequent in vivo application testing. This integrated approach ensures the development of uniquely functionalized peptides designed to meet specific immunomodulatory mechanism-of-action requirements.
Our platform supports the development of diverse peptide modalities engineered for specific immunomodulatory functions. Service offerings are tailored to the therapeutic objective and can include, but are not limited to, the following types:
Peptide-Based Checkpoint Inhibitors
Peptides engineered to either antagonize inhibitory immune checkpoints (e.g., PD-1/PD-L1, CTLA-4) or agonize stimulatory pathways, with properties enhanced for stability and tissue penetration.
Engineered Cytokine and Chemokine Analogs
Precisely tuned analogs of interleukins, interferons, or chemokines with engineered receptor specificity, signaling bias, and improved pharmacokinetics to reduce systemic toxicity.
Multispecific Immune Engagers
Facile construction of bispecific or multispecific peptide formats that direct immune effector cells to diseased sites (e.g., tumors) or co-engage distinct immune receptors for synergistic activity.
Tolerogenic Peptide Therapeutics
Peptides designed to induce antigen-specific immune tolerance by presenting defined epitopes in a tolerogenic context, for applications in autoimmune and allergic diseases.
Recognizing the distinct immunological pathways across different pathologies, we provide disease-area-focused development services. Our approach involves tailoring the ncAA incorporation strategy and validation assays to address the specific mechanistic challenges and therapeutic goals of the indication.
Combining deep expertise in GCE with a focus on practical therapeutic development, our services offer a distinct path to novel immunomodulatory peptides. The proprietary GCEngine platform accelerates the discovery of functional orthogonal systems; our integrated in vitro to in vivo validation workflow de-risks development. We are committed to providing collaborative, customized solutions to meet specific project milestones. For detailed discussions on how our GCEngine platform can advance your immunomodulatory peptide programs, please contact us.
All our services are exclusively intended for preclinical research purposes. They are not intended for diagnostic, therapeutic, or patient management applications.
A specialized platform advancing genetic code expansion through orthogonal tRNA/aaRS technologies, enabling precise ncAA incorporation for biotherapeutic development, synthetic biology, and diagnostics.